RPG Life Sciences board clears API restructuring, Actis Generics buy, PE deal

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹2847.40

prior close

₹2863.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-1.5% vs market

Pharmaceuticals peers, median of 162sector-0.7%-1.4% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.4

15m

-0.9

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1-0.6-1.5-0.7-1.4

Next day

-2.8+0.5-3.3-0.5-2.3

-3.1+1.9-5.0+0.2-3.3

-4.0+2.3-6.3+0.1-4.2

-4.3+3.6-7.9+0.5-4.8

-6.6+4.0-10.6+0.7-7.3

-7.4+4.0-11.4+1.4-8.8

15d

-6.8+4.9-11.7+0.4-7.2

-7.1+5.9-13.1+1.7-8.8

+6.8+4.8+2.0+2.7+4.2

-10.6pendingpending-2.4-8.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved three deals on July 29, 2026. (1) Sale of API business (Rs 95.06 cr revenue, 13.54% of FY26 turnover) to wholly owned subsidiary RPGAP as slump sale for about Rs 33.55 cr. (2) PE funds ILSF and Vistaject to invest Rs 243.33 cr for around 40% stake in RPGAP, up to Rs 700 cr committed for growth. (3) RPGAP to acquire 100% of Actis Generics (API intermediates) for Rs 80 cr cash. Sale closes by Sep 30, acquisition by Nov 15, 2026.

Likely market impact

API business moved to subsidiary with PE partner. No share dilution at parent. Signals focused growth strategy for both API and formulations.